Schnieders Capital Management LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,637 shares of the medical research company’s stock after purchasing an additional 1,381 shares during the quarter. Amgen makes up 1.4% of Schnieders Capital Management LLC’s portfolio, making the stock its 19th biggest position. Schnieders Capital Management LLC’s holdings in Amgen were worth $5,030,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Regency Capital Management Inc. DE bought a new stake in shares of Amgen in the 1st quarter valued at about $27,000. Maverick Capital Ltd. acquired a new stake in Amgen in the first quarter valued at approximately $27,000. Elmwood Wealth Management Inc. acquired a new stake in Amgen in the first quarter valued at approximately $31,000. Wolverine Asset Management LLC grew its holdings in Amgen by 1,587.5% in the first quarter. Wolverine Asset Management LLC now owns 135 shares of the medical research company’s stock worth $33,000 after purchasing an additional 127 shares during the last quarter. Finally, KB Financial Partners LLC acquired a new position in shares of Amgen during the first quarter worth $35,000. 74.73% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Amgen from a “sell” rating to a “hold” rating and set a $255.00 price target on the stock in a research note on Tuesday, June 29th. Oppenheimer raised their target price on Amgen from $272.00 to $277.00 and gave the stock an “outperform” rating in a research note on Monday, June 7th. BMO Capital Markets boosted their price target on Amgen from $296.00 to $301.00 and gave the company an “outperform” rating in a research note on Monday, May 31st. Mizuho started coverage on shares of Amgen in a report on Friday, September 10th. They issued a “hold” rating and a $222.00 price target on the stock. Finally, Robert W. Baird reissued a “sell” rating on shares of Amgen in a research report on Thursday, August 5th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $249.70.
Amgen (NASDAQ:AMGN) last released its earnings results on Monday, August 2nd. The medical research company reported $4.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.09 by $0.29. Amgen had a return on equity of 99.85% and a net margin of 22.55%. The firm had revenue of $6.53 billion during the quarter, compared to analysts’ expectations of $6.43 billion. On average, sell-side analysts anticipate that Amgen Inc. will post 16.41 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 8th. Investors of record on Tuesday, August 17th were issued a $1.76 dividend. This represents a $7.04 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend was Monday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 42.41%.
Amgen Company Profile
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
See Also: Options Trading – What is a Straddle?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.